THE IMPACT OF DISCOUNTING ON THE COST EFFECTIVENESS OF TISAGENLECLEUCEL FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA

被引：0
|
作者：
Carey, N. [1 ]
Mccullagh, L. [1 ]
Barry, M. [1 ]
机构：
[1] Natl Ctr Pharmacoecon, Dublin, Ireland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB125
引用
收藏
页码：S85 / S86
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
    Santasusana, Josep Maria Ribera
    de Andres Saldana, Alejandra
    Garcia-Munoz, Nuria
    Gostkorzewicz, Joana
    Martinez Llinas, Diana
    Diaz de Heredia, Cristina
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 253 - 264
  • [2] Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis
    Carey, Niamh
    Leahy, Joy
    Trela-Larsen, Lea
    McCullagh, Laura
    Barry, Michael
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2022, 38 (01)
  • [3] BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND
    Hollmann, S.
    Painter, C.
    Hogan, A.
    Wickstead, R. M.
    Goyert, N.
    Patel, S.
    Slowley, A.
    Jousseaume, E.
    El Ouagari, K.
    Zhang, J.
    Jewitt, K.
    Ma, Q.
    VALUE IN HEALTH, 2018, 21 : S25 - S25
  • [4] Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
    Verneris, Michael R.
    Ma, Qiufei
    Zhang, Jie
    Keating, Amy
    Tiwari, Ranjan
    Li, Junlong
    Yang, Hongbo
    Agarwal, Abhijit
    Pacaud, Lida
    BLOOD ADVANCES, 2021, 5 (23) : 5387 - 5395
  • [5] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
    Wakase, Shiho
    Teshima, Takanori
    Zhang, Jie
    Ma, Qiufei
    Watanabe, Yoko
    Yang, Hongbo
    Qi, Cynthia Z.
    Chai, Xinglei
    Xie, Yanwen
    Wu, Eric Q.
    Igarashi, Ataru
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 241.e1 - 241.e11
  • [6] COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVE
    Yang, H.
    Zhang, J.
    Hampe, M.
    VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [7] Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia
    Ma, Qiufei
    Zhang, Jie
    O'Brien, Elliott
    Martin, Amber L.
    Agostinho, Andrea Chassot
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (12) : 849 - 860
  • [8] The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL)
    Sharplin, Kirsty Marie
    Marks, David
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1292 - 1301
  • [9] Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
    Wang, Xiao Jun
    Wang, Yi-Ho
    Ong, Matthew Jian Chun
    Gkitzia, Christina
    Soh, Shui Yen
    Hwang, William Ying Khee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 333 - 355
  • [10] COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE
    Kattamis, A.
    Avgitidou, A.
    Chatzopoulos, S.
    Markouri, A.
    Florini, S.
    Stafylas, P.
    VALUE IN HEALTH, 2019, 22 : S452 - S452
12345